This is a great day and an amazing leap forward for the science and potential of stem cells. I hope that it will change the future of spinal cord injuries and diseases.
Irvine, CA (PRWEB) May 06, 2011
The California Institute for Regenerative Medicine (CIRM) has announced that it will give $25 million to a clinical trial that will test an embryonic stem cell-based therapy for spinal cord injuries. The trial is the first to test a therapy based on human embryonic stem cells.
Hans Keirstead, PhD, UC Irvine Professor of Anatomy and Neurobiology at the Reeve-Irvine Research Center, and Chairman of the Scientific Advisory Board of California Stem Cell (CSC) led the team that came up with the novel treatment. It involves injecting human embryonic stem cell-derived spinal cord cells into a damaged spine.
Because of CIRM rules, the company running the trials can not be disclosed. Said Keirstead, "This is a great day and an amazing leap forward for the science and potential of stem cells. I hope that it will change the future of spinal cord injuries and diseases. UC Irvine and California Stem Cell are not running or responsible for the clinical trial outcomes, but you can be assured that we will be following the study closely, and look forward to great progress.”
The money from the California Institute of Regenerative Medicine comes from Proposition 71, which voters approved in 2004.
ABOUT CALIFORNIA STEM CELL
Founded in 2005, California Stem Cell is to catalyze the efficient development of human therapies based on human embryonic stem cells. CSC has developed proprietary methods for scalable production of human motor neurons, neuronal progenitors, hepatocytes, and cardiac cells, at high purity, from hESCs.
CSC is currently developing stem cell based therapies for spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS, or Lou Gehrig's Disease). CSC also markets high-purity human cells in platforms suitable for high throughput and high content screening of conventional drug candidates using human cell substrates, predictive toxicity of conventional drugs using human cell substrates, and development of experimental research tools. CSC is a privately held Delaware Corporation with headquarters and research facilities in Irvine, CA.
CSC can economically supply large quantities of high purity cells for our own clinical development pipeline in specific application areas. CSC can also supply high purity, fully characterized, clinically relevant human cell populations to companies or other institutions for development of therapies, efficacy screening or creation of toxicity profiles for candidate drugs, or experimental research.
# # #